• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Analysis of the cardiovascular effects of co-derocrine (Hydergine).

作者信息

Clark B J, Bucher T, Waite R

出版信息

J Pharmacol. 1985;16 Suppl 3:101-11.

PMID:2869189
Abstract

The antihypertensive effect of co-dergocrine (Hydergine) has previously been thought to be due to alpha-adrenoceptor blockade and/or an action exerted in the CNS. The present experiments do not support this view. The doses necessary to inhibit vasoconstrictor responses to phenylephrine and noradrenaline by 50% in anaesthetized cats and dogs are 10-50 times that which lowers blood pressure in these species by 30 mmHg. Despite the fact that co-dergocrine is a potent alpha-adrenoceptor antagonist in isolated tissues (pA2: 8.4-9.4), its activity in vivo is too weak to contribute significantly to its effect on blood pressure. Slow intravertebral artery infusion of 10 micrograms/kg co-dergocrine produces a smaller blood pressure fall in the dog than intravenous infusion of the same dose. The reverse is true for the centrally-acting alpha 2-adrenoceptor stimulant, guanfacine. In addition, efferent splanchnic nerve activity in the cat is not affected by doses up to 100 micrograms/kg i.v. The dose of co-dergocrine depressing nerve activity by 50% is approximately 900 micrograms/kg; the dose of clonidine producing comparable inhibition is 3.4 micrograms/kg i.v. Since falls in blood pressure and heart rate can be obtained with co-dergocrine at a dose of only 10 micrograms/kg i.v., a central action cannot be considered to play a role in the cardiovascular effects of the drug in response to acute administration. Heart rate increases evoked by stimulating the accelerans nerve of ganglion-blocked cats are inhibited dose-dependently by co-dergocrine from a dose of 1 microgram/kg i.v. The drug also depresses pressor responses to stimulation of the lumbar sympathetic outflow in pithed rats. Both effects are prevented by pretreatment with the dopamine receptor antagonist, sulpiride (300 micrograms/kg). Intravenous administration of 10 micrograms/kg co-dergocrine depresses pressor responses to a psychological stimulus or raising the forequarters in conscious dogs, and produces marked falls in blood pressure and heart rate in anaesthetized, baroreceptor-denervated dogs. These effects are also abolished by sulpiride. It is concluded that the cardiovascular responses to acute administration of low doses of co-dergocrine are due to stimulation of prejunctional dopamine receptors.

摘要

相似文献

1
Analysis of the cardiovascular effects of co-derocrine (Hydergine).
J Pharmacol. 1985;16 Suppl 3:101-11.
2
Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.培高利特对正常血压和高血压犬降压作用所涉及的药理、血流动力学及生化机制。
J Pharmacol Exp Ther. 1985 Dec;235(3):798-809.
3
Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).抗高血压药物盐酸N-脒基-2-(2,6-二氯苯基)乙酰胺(BS 100-141)的药理作用
Arzneimittelforschung. 1975 Oct;25(10):1483-91.
4
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.培高利特对大鼠血压和心率降低作用的药理、血流动力学及自主神经系统机制。
J Pharmacol Exp Ther. 1984 Mar;228(3):779-91.
5
Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats.在犬和大鼠中,强效α-1肾上腺素能受体激动剂西拉唑啉(LD 3098)缺乏心脏突触前α-2肾上腺素能受体刺激特性的功能和生化证据。
J Pharmacol Exp Ther. 1982 Oct;223(1):241-50.
6
Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.ASL - 7022的心血管药理学。III. 外周血管肾上腺素能机制。
J Pharmacol Exp Ther. 1985 Mar;232(3):629-35.
7
Evidence for adrenergic and tachykinin activity in venom of the stonefish (Synanceja trachynis).关于玫瑰毒鲉(Synanceja trachynis)毒液中肾上腺素能和速激肽活性的证据。
Toxicon. 1996 May;34(5):541-54. doi: 10.1016/0041-0101(96)00012-8.
8
Cardiovascular responses to the stimulation of alpha-1 and alpha-2 adrenoceptors in the conscious dog.清醒犬对α-1和α-2肾上腺素能受体刺激的心血管反应。
J Pharmacol Exp Ther. 1986 Apr;237(1):86-91.
9
[Action of delta 9 tetrahydrocannabinol on the central cardiovascular regulation : mechanism and localization].[δ9-四氢大麻酚对中枢心血管调节的作用:机制与定位]
Encephale. 1975;1(2):121-32.
10
A new centrally acting antihypertensive (ICI 106270) which separates antihypertensive effects from sedation.一种新型的中枢性抗高血压药(ICI 106270),它能将降压作用与镇静作用区分开来。
Arzneimittelforschung. 1981;31(10):1698-703.

引用本文的文献

1
Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors.通过刺激多巴胺DA2受体抑制人体对钠缺失的醛固酮反应。
Eur J Clin Pharmacol. 1988;35(3):323-6. doi: 10.1007/BF00558273.
2
Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives.选择性D-2多巴胺受体阻滞剂舒必利对老年高血压患者中麦角隐亭降压作用的逆转。
Eur J Clin Pharmacol. 1987;33(5):519-21. doi: 10.1007/BF00544247.
3
Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.
Eur J Clin Pharmacol. 1990;39(5):435-9. doi: 10.1007/BF00280932.
4
Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.硝苯地平/考来烯胺组合在肝肾功能受损患者中的临床药代动力学。
Eur J Drug Metab Pharmacokinet. 1992 Jan-Mar;17(1):33-8. doi: 10.1007/BF03189985.